Found 18 results
Author Title Type [ Year(Asc)]
Filters: Author is Schmidt, C  [Clear All Filters]
2014
Hayes, P., Fernandez, N., Omosa-Manyonyi, G., Mpendo, J., Karita, E., Ruzagira, E., et al.. (2014). Assessment of Viral Inhibition Activity in Low Seroprevalent Adenovirus-35 Vectored HIV Vaccines +/- Adjuvanted Protein or Electroporated DNA. In HIV Research for Prevention 2014: AIDS Vaccine, Microbicide and ARV-based Prevention Science (HIVR4P). presented at the 24/09/2014, Cape Town, SA. Retrieved from http://hivr4p.org/
Mutua, G., Mutengu, L., Mpendo, J., Kilembe, W., Omosa, G., Ruzagirwa, E., et al.. (2014). Major Negative Social Impacts are Rare in Phase 1 HIV Vaccine Trials in Africa. In HIV Research for Prevention 2014: AIDS Vaccine, Microbicide and ARV-based Prevention Science (HIVR4P). presented at the 28/10/2014, Cape Town, SA. Retrieved from http://hivr4p.org/
2007
2005
G Manyonyi, O., Jaoko, W., Wakasiaka, S., Bwayo, J., Achola, N. J., Schmidt, C., et al.. (2005). Challenges Experienced By the Clinical Team During The Conduct of HIV Vaccine Clinical Trials in Kenya. In AIDS Vaccine 2005 International Conference. presented at the 06/09/2005, Montreal, Quebec, Canada.
Peters, B., Jaoko, W., Anzala, O., Judges, L., G Manyonyi, O., Sharp, A., et al.. (2005). Phase 2A Dose and Route Study of a DNA Prime MVA Boost Vaccine Candidate. In AIDS Vaccine 2005 International Conference. presented at the 06/09/2005, Montreal, Quebec, Canada.
Vardas, E., Pantaleo, G., Bart, P. A., Robinson, A., Pieterse, C., Thomas, R., et al.. (2005). Safety and Immunogenicity of MVA.HIVA by 3 Different Routes. In AIDS Vaccine 2005 International Conference. presented at the 06/09/2005, Montreal, Quebec, Canada.